A Phase 4 interventional study of Bone Allograft and Conventional Medical Management (CMM) in Sacroiliac Joint Pain, sponsored by PainTEQ, LLC. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by PainTEQ, LLC · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.
Among the 106 studies in Arthralgia with a site in United States, this one is the 20th largest by planned enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 14 of the 22 other live ones, and was the 103rd registered.
277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.
Browse Arthralgia studies →17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
PainTEQ, LLC · Sites in United States
Ages 21+
Weill Medical College of Cornell University · Sites in United States
Ages 18–75
Veterans Medical Research Foundation · Sites in United States
Ages 18–65
ESM Technologies, LLC · Sites in United States
Ages 18–40 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 20 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 73 across 218 interventional studies indexed under Arthralgia.
Median enrollment 82 across the 88 interventional studies, 144 across the 18 observational. Of the 67 that completed or were terminated, 24 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 106 have an industry lead sponsor. The 10 most frequent:
PainTEQ, LLC is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
PainTEQ, LLC has 2 studies filed under Arthralgia — fewer than ten, so there is no comparison to draw.
7 of the studies in Arthralgia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05621369Sage BionetworksPsorcast Mobile Study | 2027-01-31 |
| NCT04994249Stanford UniversityDiagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation | 2027-04-25 |
| NCT07547215PainTEQ, LLCPost-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Arthralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical evaluation is to assess the safety and effectiveness of LINQ fusion procedure for treatment of sacroiliac joint (SIJ) dysfunction compared to Conservative Medical Management (CMM).
Prospective, multi-center, open-label, randomized, clinical study. Subjects who meet the eligibility criteria and are enrolled will be randomized 2:1 to LINQ or CMM. After their 6 Month evaluations are complete, subjects in the Control Group can elect to stay in the CMM Arm or crossover to receive the LINQ procedure.
Each subject will undergo a Screening Visit, Randomization, Baseline Procedure or CMM Initiation Visit, and Follow-Up Visits through 24 Months. The primary endpoint is evaluated at the 6 Month Follow Up Visit.
Subjects that elect to crossover from the Control Group to the Treatment Group at the 6 Month Visit, will have Procedure and Follow-Up Visits through 18 Months post crossover procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in this study, a subject must meet ALL of the following criteria, as determined by the Investigator:
Age and (BMI)
Chronic SIJ-Related Pain
Diagnosis of SIJ Dysfunction
a. Has a diagnosis of SIJ dysfunction (degenerative sacroiliitis or SIJ disruption) based on ALL of the following: i. A positive Fortin's finger test; and ii. Pain elicited at least three (3) of five (5) SIJ-specific physical examination maneuvers (FABER test, Gaenslen's test, Distraction, Thigh Thrust, Compression); and iii. At least 75% reduction in pain, with associated improvement in previously painful maneuvers, for the expected duration of action following two (2) image-guided, contrast-enhanced intra-articular diagnostic SIJ injections, performed on separate visits using anesthetics with different durations of action; and iv. Completion of at least one (1) therapeutic intra-articular SIJ injection (e.g., injection) within the past 12 months.
Baseline Disability and Pain Severity
a. Baseline Oswestry Disability Index (ODI) score ≥30%; and b. Baseline SI joint pain score of ≥60 mm on a 100 mm Visual Analog Scale (VAS).
Nicotine Abstinence
a. Is able and willing to completely avoid all forms of nicotine (including smoking, vaping, e-cigarettes, tobacco, or nicotine pouches) for the entire duration of the study.
Treatment Decision
a. The treating physician has independently determined that the LINQ procedure is an appropriate treatment option for the subject's SIJ dysfunction in the course of routine clinical care, and the subject has agreed to undergo this treatment.
and Compliance
Exclusion Criteria:
Exclusion Criteria Subjects must meet none of the following criteria to be eligible for participation in this study, as determined by the Investigator:
Alternative Primary Spine Pathology
a. Presence of severe low back pain attributable to other spinal pathology, including but not limited to lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, or lumbar vertebral body fracture.
Other Sacroiliac Pathology
a. Presence of known sacroiliac joint pathology other than degenerative SIJ dysfunction, including inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathies), tumor, infection, acute fracture, or crystal arthropathy.
Non-SIJ Pain Syndromes
a. History of coccydynia or prior coccygectomy, endometriosis, cluneal neuralgia, or pudendal neuralgia.
Recent Sacral Interventions
a. Prior sacral radiofrequency ablation performed within 6 months prior to enrollment.
Recent Pelvic Trauma
a. History of major pelvic trauma within 12 months prior to enrollment.
Severe Osteoporosis
a. Prior diagnosis or suspicion of severe osteoporosis, defined as a prior bone mineral density T-score of \< -2.5 or a history of osteoporotic fracture.
Medications Detrimental to Bone or Soft-Tissue Healing
a. Current use of medications known to adversely affect bone quality or soft-tissue healing, as determined by the Investigator.
Anatomic Constraints
a. Anatomic anomalies or defects that, in the Investigator's opinion, would preclude safe or biomechanically appropriate device placement.
Systemic Inflammatory or Rheumatologic Disease
a. Presence of a chronic inflammatory rheumatologic condition, such as rheumatoid arthritis.
Centralized Pain Syndromes
a. Current diagnosis of fibromyalgia.
Infection Risk
a. Evidence of current local or systemic infection that would increase surgical risk.
High-Dose Opioid Therapy (≥90 MME/day)
a. Current use of systemic opioid analgesics at Screening/Baseline with an average daily dose ≥90 morphine milligram equivalents (MME/day), based on medication reconciliation (prescription records and subject report) and standard MME conversion factors.
Current Nicotine Use (Self-Reported)
a. Self-reported use of any nicotine-containing products (including smoking, vaping/e-cigarettes, cigars, pipes, smokeless tobacco, nicotine pouches, and nicotine replacement products) within 6 weeks prior to Screening/Baseline.
Secondary Gain or Litigation
a. Currently receiving or actively seeking workers' compensation or disability benefits or involved in injury-related litigation.
Pregnancy
a. Currently pregnant or planning to become pregnant within two (2) years following enrollment, as self-reported.
Vulnerable Populations
a. Individuals who are prisoners or wards of the state.
Substance Abuse
a. Known or suspected active drug or alcohol abuse, including opioid misuse.
Psychiatric Conditions
a. Diagnosed psychiatric disorder (e.g., schizophrenia, major depressive disorder, personality disorder) that, in the Investigator's judgment, could interfere with study participation.
Concurrent Interventional Research
a. Current participation in another clinical trial.
Neurologic Conditions Affecting Rehabilitation
a. Presence of a significant neurologic disorder that would interfere with participation in physical therapy or post procedural rehabilitation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the Treatment Arm will undergo the LINQ Procedure.
Procedure: Bone Allograft
Subjects randomized to the CMM Control Arm shall receive standardized, stepwise, non-surgical management for SIJ pain.
Other: Conventional Medical Management (CMM)
The LINQ system is intended for use in patients with SIJ disease by implantation of compatible implants to prepare the SIJ for allograft fusion.
CMM Control Arm shall receive standardized, stepwise, non-surgical management for SIJ pain.
Also known as: Non-Surgical Management
Composite Success Responder Rate at Month 6
Unit of Measure: Percentage of participants Description: The primary endpoint is a single binary (Yes/No) composite responder classification per subject at Month 6. A subject is classified as a composite success responder ONLY if ALL three of the following criteria are met: Pain Improvement: Reduction in SIJ pain VAS score of ≥20 mm from baseline to Month 6 (VAS measured on 0-100 mm scale). Safety: Absence of any device-related or procedure-related SAEs through Month 6 (Day 180). Surgical Reintervention: No surgical reintervention for SIJ fusion through Month 6 (Day 180), including device removal (complete or partial), device revision or replacement, or reoperation at the index SIJ. Subjects meeting all three components are classified as responders; the outcome is reported as the percentage (%) of participants classified as responders.
Time frame: Month 6
Proportion of Participants Achieving Both a ≥20 mm Reduction in SIJ Pain VAS and a ≥15 Point Reduction in ODI
Composite responder analysis based on two validated patient-reported outcomes. Pain intensity is measured using a 100 mm Visual Analog Scale (VAS) anchored by 0 mm ("no pain") and 100 mm ("worst imaginable pain"); higher scores indicate greater pain severity. Disability is measured using the Oswestry Disability Index (ODI), a 10-item questionnaire assessing low back pain-related disability across domains of daily living, scored 0-100; higher scores indicate greater disability. A participant is classified as a responder if they achieve BOTH a reduction of ≥20 mm from baseline in sacroiliac joint (SIJ) pain VAS AND a reduction of ≥15 points from baseline in ODI. The proportion of responders will be reported and a higher proportion indicates greater clinical improvement.
Time frame: Months 1, 3, 6, 12, 18, 24
Visual Analog Scale (VAS)
The Visual Analog Scale (VAS) is a patient-reported measure of pain intensity assessed using a 100 mm horizontal line anchored by 0 mm ("no pain") and 100 mm ("worst imaginable pain"). Scores range from 0 to 100 mm, with higher scores indicating greater pain severity. Change from baseline in VAS score and proportion of participants achieving a minimum clinically important difference (MCID) in pain intensity will be assessed. MCID is defined as a reduction of ≥20 mm from baseline on the 0-100 mm scale. Higher proportions indicate greater clinical improvement.
Time frame: Months 1, 3, 6, 12, 18, 24.
Oswestry Disability Index (ODI)
The Oswestry Disability Index (ODI) is a validated patient-reported questionnaire assessing disability related to low back pain across 10 domains of daily living. Scores range from 0 to 100, with higher scores indicating greater disability. Change from baseline in ODI score and proportion of participants achieving a minimum clinically important difference (MCID) in disability will be assessed using the Oswestry Disability Index (ODI). MCID is defined as a reduction of ≥15 points from baseline on the 0-100 scale. Higher proportions indicate greater clinical improvement.
Time frame: Months 1, 3, 6, 12, 18, 24
Patient-Reported Outcomes Measurement Information System (PROMIS-29+2)
The Patient-Reported Outcomes Measurement Information System 29-Item Profile v2.1 + 2 (PROMIS-29+2) assesses multiple health domains including physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles, pain interference, and cognitive function. Domain scores are reported as T-scores standardized to a mean of 50 and standard deviation of 10 in the general population, with a typical range of approximately 20 to 80. Higher scores indicate more of the domain being measured (e.g., worse symptoms for anxiety, depression, fatigue, sleep disturbance, pain interference, and cognitive concerns; and better functioning for physical function and social participation). Change from baseline in T-scores will be evaluated.
Time frame: Months 1, 3, 6, 12, 18, 24
EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire is a standardized measure of health-related quality of life assessing five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a single index score using country-specific value sets. The index score typically ranges from less than 0 (health states worse than death) to 1 (perfect health), where higher scores indicate better health status. Change from baseline in EQ-5D-5L index scores will be evaluated.
Time frame: Months 1, 3, 6, 12, 18, 24
Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change (PGIC) is a patient-reported measure assessing overall change in health status since the start of treatment. It is a 7-point ordinal scale with responses ranging from 1 ("very much improved") to 7 ("very much worse"). Lower scores indicate greater improvement, and higher scores indicate worsening. The distribution of PGIC responses across categories will be summarized.
Time frame: Months 1, 3, 6, 12, 18, 24
Medication use
Medication use will be assessed at each visit, including opioid and non-opioid pain medications. Opioid consumption will be quantified as daily morphine milligram equivalents (MME), calculated using standard conversion factors. MME values range from 0 upward, with higher values indicating greater opioid use. Change from baseline in daily MME will be evaluated. Additional analyses may include the proportion of participants reducing or discontinuing opioid use over time.
Time frame: Months 1, 3, 6, 12, 18, 24
Incidence of Adverse Events
Safety will be assessed by evaluating all adverse events (AEs) reported from the time of the index procedure through study completion. AEs will be characterized by severity, seriousness, and relatedness to the device and/or procedure. The number and proportion of participants experiencing one or more device- or procedure-related AEs and serious adverse events (SAEs) will be summarized.
Time frame: Months 1, 3, 6, 12, 18, 24
Characterization of Procedure Details and Healthcare Utilization
Supportive data will be collected to characterize the index procedure and subsequent healthcare utilization. Procedure details include procedure time, anesthesia type, fluoroscopy time, and technical success. Healthcare utilization includes pain-related medication use, injections, additional interventions or reoperations, and pain-related healthcare visits from baseline through study completion. Data will be summarized descriptively.
Time frame: Months 1, 3, 6, 12, 18, 24.
Plan to share: No — Sponsored Study
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.